Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016–2017

Population versus individual protection by pneumococcal conjugate vaccination

(2019) Keith P Klugman et al.   LANCET

Examining Duration of Protection: Should a Booster Dose Be Part of All Infant Pneumococcal Conjugate Vaccine Programs?

(2018) Cynthia G Whitney   CLINICAL INFECTIOUS DISEASES

Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis—Burkina Faso, 2014–2015

(2018) Dinanibè Kambiré et al.   JOURNAL OF INFECTION

Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine

(2018) Catherine H. Bozio et al.   PLoS One

Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Joseph Raymond Zunt et al.   LANCET NEUROLOGY

Can infant vaccination prevent pneumococcal meningitis outbreaks in sub-Saharan Africa?

(2017) James M. Stuart   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign

(2017) Alpha Oumar Diallo et al.   PLoS One

An outbreak of pneumococcal meningitis among older children (≥5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana

(2016) Brenda Anna Kwambana-Adams et al.   BMC INFECTIOUS DISEASES

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden

(2016) Ilias Galanis et al.   EUROPEAN RESPIRATORY JOURNAL

Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study

(2016) Grant A Mackenzie et al.   LANCET INFECTIOUS DISEASES

Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children

(2016) Brian A. Kendall et al.   VACCINE

Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2–6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands

(2016) Gertjan H.J. Wagenvoort et al.   VACCINE

Nationwide Trends in Bacterial Meningitis before the Introduction of 13-Valent Pneumococcal Conjugate Vaccine—Burkina Faso, 2011–2013

(2016) Dinanibè Kambiré et al.   PLoS One

Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children

(2015) Liset Olarte et al.   CLINICAL INFECTIOUS DISEASES

Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of pneumococcal meningitis in children

(2015) A. G. CHAPOUTOT et al.   EPIDEMIOLOGY AND INFECTION

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

(2015) Pauline A Waight et al.   LANCET INFECTIOUS DISEASES

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Antipneumococcal Seroprevalence and Pneumococcal Carriage During a Meningococcal Epidemic in Burkina Faso, 2006

(2013) S. Yaro et al.   JOURNAL OF INFECTIOUS DISEASES

U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination

(2013) Marie R. Griffin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sequential Triplex Real-Time PCR Assay for Detecting 21 Pneumococcal Capsular Serotypes That Account for a High Global Disease Burden

(2012) F. C. Pimenta et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

(2012) Ryan T Novak et al.   LANCET INFECTIOUS DISEASES

Pneumococcal serotype distribution among meningitis cases from Togo and Burkina Faso during 2007–2009

(2012) Bradford D. Gessner et al.   VACCINE

Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience

(2012) Mamoudou H. Djingarey et al.   VACCINE

Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose

(2011) K.P. Klugman et al.   VACCINE

Immunogenicity of a Reduced Schedule of Pneumococcal Conjugate Vaccine in Healthy Infants and Correlates of Protection for Serotype 6B in the United Kingdom

(2010) David Goldblatt et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Incidence, Seasonality, Age Distribution, and Mortality of Pneumococcal Meningitis in Burkina Faso and Togo

(2009) Yves Traore et al.   CLINICAL INFECTIOUS DISEASES

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

(2009) Katherine L O'Brien et al.   LANCET